Practice
Ranibizumab and the eye
Jason Noble and Varun Chaudhary
CMAJ April 19, 2011 183 (7) 822; DOI: https://doi.org/10.1503/cmaj.090574
Article Figures & Tables
Figures
In this issue
Article tools
Respond to this article
Ranibizumab and the eye
Jason Noble, Varun Chaudhary
CMAJ Apr 2011, 183 (7) 822; DOI: 10.1503/cmaj.090574
Jump to section
- Article
- Ranibizumab is the current standard of care for most types of wet age-related macular degeneration
- Most patients given ranibizumab still have baseline visual acuity at two years
- Patients who have blurred vision, pain and red eye after ranibizumab injection should be referred for urgent ophthalmic evaluation
- Ranibizumab is delivered by injection into the vitreous cavity
- Systemic adverse effects after ranibizumab injection are rare
- Footnotes
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.